About RenovoRx (RNXT)

RenovoRx, Inc. (RNXT) is a medical technology company specializing in the development and commercialization of innovative drug delivery systems. The company's primary focus is on the treatment of solid tumors, with a particular emphasis on pancreatic cancer. RenovoRx's flagship product, the RenovoCath System, is a unique device that enables targeted delivery of therapeutic agents directly to the tumor site. This localized approach offers several advantages over traditional systemic chemotherapy, including increased drug concentration at the tumor site and reduced systemic toxicity.

The RenovoCath System utilizes a dual-balloon catheter to isolate the tumor and create a controlled environment for drug infusion. The device can be navigated within the vasculature using standard endovascular techniques, allowing for precise placement and targeting. Once in position, the RenovoCath System delivers the therapeutic agent through the catheter, directly to the tumor site. This localized delivery approach has shown promising results in early clinical trials, with significant tumor response rates and improved patient outcomes.